Roscoff-based SeaBeLife, a BioTech firm growing revolutionary drug candidates supposed to dam mobile necrosis, as we speak publicizes a pre-Collection A funding spherical price €2 million.
The financing was led by historic investor iXLife, alongside different longstanding shareholders Breizh Angels, WeLikeStartup, Angels Santé and the Enterprise Angels des Grandes Ecoles. This spherical welcomes new buyers, together with INEXT and Femmes Enterprise Angels, the primary women-only enterprise angels’ community in Europe.
“The renewed backing from our longstanding buyers, along with the addition of recent companions, is a transparent sign of confidence in our imaginative and prescient and growth technique, and I’m extraordinarily grateful for his or her assist,” stated Morgane Rousselot, PhD, CEO and Co-founder of SeaBeLife. “This fundraising is a decisive step in the direction of medical trials and reinforces our ambition to create a brand new technology of cutting-edge therapies able to blocking two main pathways for programmed cell dying. We are actually actively getting ready for a Collection A funding spherical to maintain this momentum.”
Based in 2019, SeaBeLife focuses on growing novel small molecules that concurrently goal two main regulated cell dying pathways, necroptosis and ferroptosis, to fulfill key medical wants in acute, uncommon or continual indications the place there isn’t a therapeutic different.
This primary-in-class method is reportedly distinctive, as there may be at the moment no twin inhibitor concentrating on these pathways accessible in the marketplace. At the beginning of 2025, the corporate delivered promising preclinical efficacy outcomes for its SBL03 drug candidate in geographic atrophy, a extreme type of dry AMD.
The corporate is focusing its efforts on two flagship programmes: SBL03 for dry AMD, and SBL01 for extreme acute hepatitis, two excessive medical want indications for which the potential market is price a number of billion euros.
“Now we have backed SeaBeLife for a number of years and the most recent in vivo knowledge validates the worth and potential of the corporate’s dual-targeted method. By concurrently blocking two types of regulated cell dying, SeaBeLife uniquely shields organs from harm, highlighting its transformative potential to offer sufferers with uncommon or continual ailments with a brand new therapeutic possibility,” stated Jean-Pierre Kinet, chairman of iXLife.
This funding marks a key milestone for SeaBeLife by supporting the event of two of the corporate’s drug candidates – one aimed toward dry age-related macular degeneration (AMD) and the opposite for extreme acute hepatitis. The primary medical trial is ready to begin in 2026.
Additional to this financing spherical, Marie-Pierre Sbardella, common secretary of Femmes Enterprise Angels, joins the SeaBeLife Strategic Committee.
“We at INEXT are impressed by SeaBeLife’s disruptive know-how, which concurrently blocks two regulated cell dying pathways, defending the organs from severe ailments. Its first-in-class method, which is supported by promising preclinical outcomes, positions SeaBeLife as a key participant in the way forward for biotech. We’re proud to have contributed to this fundraising and to assist the corporate’s development,” stated Eric Valat, chairman of INEXT.
Since inception, SeaBeLife has raised €9 million in capital and public financing. It’s led by CEO and Co-founder Morgane Rousselot, who holds a PhD in biochemistry from Sorbonne College/French Nationwide Middle for Scientific Analysis (CNRS)/Roscoff Marine Station.
The corporate relies on the analysis work of Stéphane Bach, PhD (CNRS), Marie-Thérèse Dimanche-Boitrel (Analysis Institute for Environmental and Occupational Well being — IRSET) and Claire Delehouzé, PhD, scientific director and companion.
